Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis b vaccine (National Cancer Institute)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The hepatitis b vaccine is a recombinant subunit vaccine designed to provide active immunity against infection caused by all known subtypes of the hepatitis B virus (HBV). In the specific context of the National Cancer Institute (NCI) Phase II clinical trial (NCT02863926), it is utilized as a clinical probe to evaluate the efficacy of Glyco-Recombinant Human Interleukin-7 (CYT107) in restoring immune competence in older adults (aged 60 and over) who have recently completed chemotherapy for breast, colon, or bladder cancer. These patients often experience chemotherapy-induced immunosuppression and immunosenescence, which can lead to suboptimal responses to standard vaccinations. The vaccine works by presenting the hepatitis B surface antigen (HBsAg) to the immune system, thereby stimulating the production of protective antibodies.
- Other names
- Hepatitis B virus vaccineHepB vaccineHBV vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis b vaccine (National Cancer Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis b vaccine (National Cancer Institute).